Delivery of endostatin in experimental cancer therapy.
Endostatin, the 20 kDa C-terminal fragment of collagen XVIII, has been shown to be an effective inhibitor of tumour angiogenesis and growth in different experimental systems and is currently in Phase II/III clinical trials. One challenging aspect of anti-angiogenic treatment is the mode of delivery of the active compound. In this paper we review some of the basic knowledge of endostatin and look specifically into the different possible ways in which endostatin may be administered.
Sorensen
Dag R
DR
Department of Comparative Medicine, Rikshospitalet, University of Oslo, Norway. d.r.sorensen@labmed.uio.no
Read
Tracy-Ann
TA
D020533:Angiogenesis Inhibitors / Q000235:genetics / Q000627:therapeutic use*; D000818:Animals; D019149:Bioreactors; D017321:Clinical Trials, Phase I as Topic; D003094:Collagen / Q000235:genetics / Q000627:therapeutic use*; D043170:Collagen Type XVIII; D043169:Endostatins; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010446:Peptide Fragments / Q000235:genetics / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D043170:Collagen Type XVIII; D043169:Endostatins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D003094:Collagen